Abstract
Purpose
To explore supports and coping strategies used during attempts to discontinue antipsychotic medication and test for associations with success.
Method
144 people who were taking or had taken antipsychotics completed The Experiences of Antipsychotic Medication Survey. Among them, 105 people had made at least one discontinuation attempt and answered a series of questions about their most recent attempt to stop. Content analysis and Chi-square tests of independence were used to categorise the data and explore associations. Success was defined as stopping all AM use irrespective of the duration of the medication-free period or whether relapse occurred, which were explored separately.
Results
Among the 105 people who had attempted discontinuation, 61.9% described unwanted withdrawal effects and 27.6% of the group described psychotic or manic relapse during the withdrawal period. Within this group 55% described successfully stopping all AM for varying lengths of time, half reported no current use, and half described having some form of professional, family, friend, and/or service user or peer support for their attempt. Having support was positively associated with success and negatively associated with both current use, and relapse during withdrawal. A range of coping efforts were described, but having coping strategies failed to show significant associations with any of the dependent variables explored. Among those who described successfully stopping, some described returning to AM for short periods when needed, while others reported managing well with alternative methods alone.
Conclusions
Findings cannot be readily generalised due to sampling constraints, but results suggest a wide range of supports and coping strategies may be used when attempting to discontinue antipsychotics. Many people may attempt to discontinue antipsychotics without any support. Those who have support for their attempts may be significantly less likely to relapse during withdrawal and more likely to succeed in their attempt. There is a pressing need for further research in this area.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223
Cooper D, Moisan J, Gaudet M, Abdous B, J Gregoire (2005) Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry 50:901–908
Nishikawa T, Hayashi T, Koga I, Uchida Y. (2007) Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study. Psychiatry: Interpers Biol Process 70:68
Harrow MH, Jobe TH, Faull RN (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. PsycholMed 42:2145–2155
Schooler NR, Goldberg SC, Boothe H, Cole JO (1967) One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry 123:986
Chouinard G, Chouinard V (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77:69
Baldessarini RJ, Viguera AC (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52:189
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/ discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913
Landolt K, Rössler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS et al (2016) Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizophrenia Res 172:145–151
Steiner W, Laporta M, Chouinard G (1990) Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand 81:437–440
Chouinard G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment, Schizophr Res 5:21–33
Moncrieff J (2013) The bitterest pills: the troubling story of antipsychotic drugs. Palgrave Macmillan, London
Moncrieff J, Cohen D, Porter S (2013) The psychoactive effects of psychiatric medication: the elephant in the room. J Psychoact Drugs 45:409–415
Byrne R, Davies L, A Morrison (2010) Priorities and preferences for the outcomes of treatment of psychosis: a service user perspective. Psychosis 2:210–217
McGorry P, Alvarez-Jimenez M, Killackey E (2013) Antipsychotic medication during the critical period following remission from first- episode psychosis: less is more. JAMA Psychiatry 70:898
Breggin PR (2013) Psychiatric Drug Withdrawal: a guide for prescribers, therapists, patients and their families. Springer Publishing Company, New York
Hall W (2012) The harm reduction guide to coming off psychiatric drugs, 2nd edn., The Icarus Project and Freedom Centre, USA
May R, Jhugroo A, Thomas P (2016) Coming off psychiatric medication (Website). http://www.comingoff.com/
Geyt GL, Awenat Y, Tai S, Haddock G (2016) Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res 26:1–16
Salomon C, Hamilton B (2013) “All roads lead to medication?” Qualitative responses from an australian first- person survey of antipsychotic discontinuation. Psychiatr Rehabil J 36:160–165
Salomon C, Hamilton B, Elsom S (2014) Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs 21:917
Jung E, Wiesjahn M, Wendt H, Bock T, Rief W, Lincoln TM (2016) Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol Med 46:2179–2188
Larsen-Barr MT (2016) Experiencing antipsychotic medication: from first prescriptions to attempted discontinuation. University of Auckland doctoral thesis, New Zealand
Read J, Cartwright C, Gibson K (2014) Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res 216:67–73
Zipursky RB, Menezes NM, Streiner DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152:408–414
Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients: Review of the literature. Arch Gen Psychiatry 52:173–188
Davidson L (2011) Recovery from psychosis: What’s love got to do with it? Psychosis–Psychol Soc Integr Approaches 3:105–114
Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L (2009) Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J 33:38–46
Gibson S, Brand S, Burt S, Boden Z, O Benson (2013) Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry 13:153
Morrison AP, Hutton P, Shiers D, Turkington D (2012) Antipsychotics: is it time to introduce patient choice? Br J Psychiatry 201:83–84
Bentall RP, Morrison AP (2002) More harm than good: the case against using anti-psychotic drugs to prevent severe mental illness. J Mental Health 11:351–356
del Barrio LR, Cyr C, Benisty L, Richard P (2013) Autonomous Medication Management (GAM): new perspectives on well-being, quality of life and psychiatric medication/Gestao Autonoma da Medicacao (GAM): novas perspectivas sobre bem-estar, qualidade de vida e medicacao psiquiatrica.(Author abstract), Ciencia & Saude Coletiva. 18
The Health and Disability Commissioner (1996) The code of health and disability services consumers’ rights, Wellington
Irwin E, Mitchell L, Durkin L, Douieb B (1972) The need for a mental patients union (The Fish Pamphlet). Self-published, London, England
Survivors History Group (2016) Mental health and survivors’ movements and context. http://studymore.org.uk/mpu.htm
Campbell P, Roberts A (2009) Survivors’ history. Life Day 13:33–36
Gawith L, Abrams P (2006) Long journey to recovery for Kiwi consumers: recent developments in mental health policy and practice in New Zealand, Australian Psychologist, vol 41, pp 140–148
Roth S, Cohen LJ (1986) Approach, Avoidance, and Coping With Stress. Am Psychol 41:813–819
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest. Data collection and statistical analyses were carried out by the first author as part of a doctoral research project in the School of Psychology at The University of Auckland. To request a copy of the study protocol email Miriam Larsen-Barr mbar114@aucklanduni.ac.nz.
Rights and permissions
About this article
Cite this article
Larsen-Barr, M., Seymour, F., Read, J. et al. Attempting to stop antipsychotic medication: success, supports, and efforts to cope. Soc Psychiatry Psychiatr Epidemiol 53, 745–756 (2018). https://doi.org/10.1007/s00127-018-1518-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00127-018-1518-x